AUL
AXSM icon

AlphaGrep UK Ltd’s Axsome Therapeutics AXSM Stock Holding History

AlphaGrep UK Ltd’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$345K Buy
2,044
+481
+31% +$83.1K 0.1% 442
2025
Q4 		$285K Buy
+1,563
New +$218K 0.1% 459

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AlphaGrep UK Ltd's AXSM Position: Q1 2026 in Review

AlphaGrep UK Ltd increased its Axsome Therapeutics (AXSM) stake by 31% in Q1 2026, buying an estimated $83.1K and bringing the position to 2,044 shares worth $345K. The position accounts for 0.1% of the portfolio, ranked #442.

AlphaGrep UK Ltd first reported a position in AXSM in Q4 2025 and has held it in 2 quarters since. 410 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • AlphaGrep UK Ltd held 2,044 shares of Axsome Therapeutics worth $345K as of Q1 2026.
  • AlphaGrep UK Ltd bought 481 Axsome Therapeutics shares in Q1 2026, an estimated $83.1K.
  • Axsome Therapeutics made up 0.1% of AlphaGrep UK Ltd's portfolio in Q1 2026, its #442 holding.
  • AlphaGrep UK Ltd first reported a position in Axsome Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 410 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on AlphaGrep UK Ltd's 13F filing for Q1 2026, filed 13 Aug 2026.